CRISPR Therapeutics AG Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2015 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: CRISPR Therapeutics AG quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2015 to Q2 2024.
CRISPR Therapeutics AG Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $23.7M, a 8.76% increase year-over-year.
CRISPR Therapeutics AG Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $81.5M, a 9.47% decline year-over-year.
CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2023 was $81M, a 17.3% decline from 2022.
CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2022 was $97.9M, a 4.34% decline from 2021.
CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2021 was $102M, a 55.1% increase from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	$81.5M	$23.7M	+$1.91M	+8.76%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-05
Q1 2024	$79.6M	$19.4M	-$1.47M	-7.04%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-08
Q4 2023	$81M	$18.4M	-$4.39M	-19.2%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-21
Q3 2023	$85.4M	$20M	-$4.58M	-18.6%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-06
Q2 2023	$90M	$21.8M	-$3.09M	-12.4%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-05
Q1 2023	$93.1M	$20.9M	-$4.87M	-18.9%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-08
Q4 2022	$97.9M	$22.8M	-$2.96M	-11.5%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-21
Q3 2022	$101M	$24.5M	-$1.66M	-6.32%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-06
Q2 2022	$103M	$24.9M	-$3.48M	-12.3%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-07
Q1 2022	$106M	$25.7M	+$3.65M	+16.5%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-08
Q4 2021	$102M	$25.8M	+$6.84M	+36.1%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-21
Q3 2021	$95.6M	$26.2M	+$8.96M	+52%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-01
Q2 2021	$86.6M	$28.3M	+$12.6M	+80.5%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-08
Q1 2021	$74M	$22.1M	+$7.94M	+56.1%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-09
Q4 2020	$66M	$18.9M	+$7.07M	+59.7%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-21
Q3 2020	$58.9M	$17.2M	+$2.47M	+16.7%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-03
Q2 2020	$56.5M	$15.7M	+$3.5M	+28.7%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-07-29
Q1 2020	$53M	$14.2M	+$3.46M	+32.3%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-04-27
Q4 2019	$49.5M	$11.9M	-$2.19M	-15.6%	Oct 1, 2019	Dec 31, 2019	10-K	2022-02-15
Q3 2019	$51.7M	$14.8M	+$5.71M	+62.9%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-10-28
Q2 2019	$46M	$12.2M	+$2.72M	+28.7%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-07-27
Q1 2019	$43.3M	$10.7M	+$4.02M	+60.3%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-04-28
Q4 2018	$39.3M	$14M	+$6.61M	+89%	Oct 1, 2018	Dec 31, 2018	10-K	2021-02-16
Q3 2018	$32.6M	$9.07M	+$3.84M	+73.5%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-10-28
Q2 2018	$28.8M	$9.48M	+$5.25M	+124%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-07-29
Q1 2018	$23.6M	$6.67M	+$2.93M	+78.1%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-04-29
Q4 2017	$20.6M	$7.43M	+$3.4M	+84.5%	Oct 1, 2017	Dec 31, 2017	10-K	2020-02-12
Q3 2017	$17.2M	$5.23M	+$2.93M	+128%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-07
Q2 2017	$14.3M	$4.23M	+$730K	+20.9%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-07
Q1 2017	$13.6M	$3.75M	+$2.72M	+267%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-08
Q4 2016	$10.8M	$4.03M			Oct 1, 2016	Dec 31, 2016	10-K	2019-02-25
Q3 2016		$2.29M	+$1.26M	+123%	Jul 1, 2016	Sep 30, 2016	10-Q	2017-11-08
Q2 2016		$3.5M			Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-10
Q1 2016		$1.02M			Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-11
Q3 2015		$1.03M			Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-22

* An asterisk sign (*) next to the value indicates that the value is likely invalid.